Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on Phillips Edison, Lowers Price Target to $31 By Benzinga Newsdesk July 15, 11:58 AM Morgan Stanley analyst Richard Hill maintains Phillips Edison (NASDAQ:PECO) with a Equal-Weight and lowers the price target from $32 to $31. PECO
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on Phillips 66, Raises Price Target to $105 By Benzinga Newsdesk July 15, 11:56 AM Morgan Stanley analyst Connor Lynagh maintains Phillips 66 (NYSE:PSX) with a Equal-Weight and raises the price target from $100 to $105. PSX
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Underweight on Pentair, Lowers Price Target to $41 By Benzinga Newsdesk July 15, 11:54 AM Morgan Stanley analyst Joshua Pokrzywinski maintains Pentair (NYSE:PNR) with a Underweight and lowers the price target from $49 to $41. PNR
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on PBF Energy, Raises Price Target to $36 By Benzinga Newsdesk July 15, 11:50 AM Morgan Stanley analyst Connor Lynagh maintains PBF Energy (NYSE:PBF) with a Equal-Weight and raises the price target from $34 to $36. PBF
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $54 By Benzinga Newsdesk July 15, 11:48 AM Morgan Stanley analyst Drew Ranieri maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and lowers the price target from $62 to $54. NUVA
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Underweight on NeuroPace, Lowers Price Target to $5.5 By Benzinga Newsdesk July 15, 11:42 AM Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Underweight and lowers the price target from $6 to $5.5. NPCE
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $102 By Benzinga Newsdesk July 15, 11:40 AM Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $100 to $102. NBIX
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on Montrose Environmental Gr, Lowers Price Target to $51 By Benzinga Newsdesk July 15, 11:36 AM Morgan Stanley analyst Matthew Sharpe maintains Montrose Environmental Gr (NYSE:MEG) with a Equal-Weight and lowers the price target from $56 to $51. MEG
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on Medtronic, Lowers Price Target to $103 By Benzinga Newsdesk July 15, 11:33 AM Morgan Stanley analyst Cecilia Furlong maintains Medtronic (NYSE:MDT) with a Equal-Weight and lowers the price target from $114 to $103. MDT
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Overweight on Marathon Petroleum, Raises Price Target to $120 By Benzinga Newsdesk July 15, 11:29 AM Morgan Stanley analyst Connor Lynagh maintains Marathon Petroleum (NYSE:MPC) with a Overweight and raises the price target from $115 to $120. MPC